Abstract
Response: Dr Mascitelli and colleagues indicate that our exploratory analysis of the relative effects of high dose atorvastatin on secondary stroke prevention in men and women1 did not mention an increased risk of hemorrhagic stroke with treatment. The stroke outcomes included all strokes (ischemic and hemorrhagic). It is not appropriate to perform analyses of subgroups of subgroups.2 Caution must always be used when conducting exploratory analyses.3 In this report, we appropriately tested for statistical interactions between treatment and gender for the SPARCL prespecified primary and secondary end points and found no statistical heterogeneity in the benefit of treatment. In …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
